IP Library › Granted Patent US 12,195,767
Granted Patent B2
US 12,195,767 · App. 16/962,552 · Granted Jan 14, 2025

Adeno-associated virus gene therapy for 21-hydroxylase deficiency

Inventors: Pierre Bougneres (Chaville, FR); Guangping Gao (Westborough, MA)
Assignee: Adrenas Therapeutics, Inc.
C12N9/0071A61K48/005C12N7/00C12N15/86C12N2750/14143C12Y114/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,195,767
App. No.
16/962,552
Granted
Jan 14, 2025
Kind
B2
Abstract

Disclosed herein are recombinant adeno-associated viral vectors expressing 21-hydroxylase (21OH) protein and related uses for treating 21OH deficiency.

Claims (26)

1. A recombinant adeno-associated virus (rAAV) particle, comprising: an rAAV vector, wherein the rAAV vector comprises a nucleic acid molecule, comprising (i) at least one AAV inverted terminal repeat (ITR) and (ii) a non-AAV nucleotide sequence encoding a 21-hydroxylase (21 OH) protein comprising an amino acid sequence having at least 95% identity to SEQ ID NO: 1, wherein the non-AAV nucleotide sequence is operably linked to a CAG promoter, and wherein the rAAV particle is an AAV5 serotype.

2. The rAAV particle of claim 1 , wherein the 21OH protein is human 21OH protein.

3. The rAAV particle of claim 1 , wherein the non-AAV nucleotide sequence encoding a 21OH protein comprises or consists of the human 21OH (CYP21A2) cDNA.

4. The rAAV particle of claim 3 , wherein the non-AAV nucleotide sequence encoding a 21OH protein comprises or consists of a codon-optimized nucleotide sequence.

5. The rAAV particle of claim 1 , wherein the non-AAV nucleotide sequence encoding a 21OH protein;

(i) comprises or consists of SEQ ID NO:50, or

(ii) encodes the amino acid sequence of SEQ ID NO:1, or

(iii) encodes an amino acid sequence at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:1.

6. The rAAV particle of claim 1 , wherein the promoter comprises or consists of the nucleotide sequence of SEQ ID NO: 2.

7. The rAAV particle of claim 1 , wherein the ITR is an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, rh10, or rh74 serotype ITR.

8. A recombinant adeno-associated virus (rAAV) particle, comprising: an rAAV vector, wherein the rAAV vector comprises a nucleic acid molecule comprising a non-AAV nucleotide sequence encoding a 21-hydroxylase (21OH) protein comprising an amino acid sequence having at least 95% identity to SEQ ID NO: 1, wherein:

(i) the non-AAV nucleotide sequence is operably linked to a CAG promoter;

(ii) the rAAV vector comprises at least one AAV inverted terminal repeat (ITR), wherein the ITR is from an AAV of serotype AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, rh10, or rh74; and

(iii) the rAAV particle is an AAV5 serotype.

9. A pharmaceutical composition comprising the rAAV particle of claim 1 , and a pharmaceutically acceptable carrier, diluent or excipient.

10. A method of producing an rAAV particle, the method comprising culturing a host cell containing: (a) the rAAV vector comprising a nucleic acid molecule, comprising (i) at least one AAV inverted terminal repeat (ITR) and (ii) a non-AAV nucleotide sequence encoding a 21-hydroxylase (21OH) protein comprising an amino acid sequence having at least 95% identity to SEQ ID NO: 1, wherein the non-AAV nucleotide sequence is operably linked to a CAG promoter; (b) a nucleic acid molecule encoding an AAV rep protein; (c) a nucleic acid molecule encoding at least one AAV capsid protein and (d) sufficient helper functions for packaging the rAAV particle, wherein the rAAV particle is an AAV5 serotype.

11. A method of expressing 21-hydroxylase (21OH) in a subject in need thereof, comprising providing a therapeutically effective amount of the rAAV particle of claim 1 to the subject, thereby expressing 21OH in the subject.

12. The method of claim 11 , wherein the 21OH is expressed in the subject's adrenal cortex, adrenal medulla, adrenal stem cells, adrenal progenitor cells, liver, or ovary.

13. A method of treating a subject with 21-hydroxylase deficiency (21OHD), comprising providing a therapeutically effective amount of the rAAV particle of claim 1 to the subject, thereby treating 21OHD in the subject.

14. The method of claim 13 , wherein the rAAV particle or a composition comprising the rAAV particle, is administered to the subject intravenously, by direct injection into the adrenal gland via open surgery or laparoscopy, or by injection into an adrenal artery via catheterization.

15. The method of claim 13 , wherein the subject is affected with congenital adrenal hyperplasia and/or the Prader stage IV or V form of 21OHD.

16. The rAAV particle of claim 1 , wherein the rAAV vector further comprises a Kozak sequence.

17. The rAAV particle of claim 1 , wherein the rAAV vector further comprises an miR-122 binding site.

18. The method of claim 11 , wherein the rAAV article, or a composition comprising the rAAV particle, is administered to the subject intravenously, by direct injection into the adrenal gland via open surgery or laparoscopy or by injection into an adrenal artery via catheterization.

19. A recombinant adeno-associated virus (rAAV) particle, comprising: an rAAV vector, wherein the rAAV vector comprises a nucleic acid molecule, comprising a non-AAV nucleotide sequence encoding a human 21-hydroxylase (21OH) protein comprising an amino acid sequence having at least 95% identity to SEQ ID NO: 1 and an miR-122 binding site, wherein the non-AAV nucleotide sequence encoding a human 21-hydroxylase (21OH) protein is operably linked to a CAG promoter, and wherein the rAAV particle is an AAV5 serotype.

20. The rAAV vector of claim 19 , wherein the non-AAV nucleotide sequence encoding a 21OH protein comprises or consists of a codon-optimized nucleotide sequence.

Assignments (6)
RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL Recorded Mar 5, 2025
From: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
To: BRIDGEBIO PHARMA, INC.; QED THERAPEUTICS, INC.; EIDOS THERAPEUTICS, INC.; ML BIO SOLUTIONS INC.; CALCILYTIX THERAPEUTICS INC.; ADRENAS THERAPEUTICS INC.; PHOENIX TISSUE REPAIR, INC.; NAVIRE PHARMA, INC.; VENTHERA, INC.; MOLECULAR SKIN THERAPEUTICS, INC.; CANTERO THERAPEUTICS, INC.; COA THERAPEUTICS, INC.; PORTAL THERAPEUTICS, INC.; BRIDGEBIO GENE THERAPY RESEARCH, INC.; FERRO THERAPEUTICS, INC.
Reel/Frame 070551/0095 →
SECURITY INTEREST Recorded Jan 19, 2024
From: BRIDGEBIO PHARMA, INC.; QED THERAPEUTICS, INC.; EIDOS THERAPEUTICS, INC.; THERAS, INC.; ML BIO SOLUTIONS INC.; CALCILYTIX THERAPEUTICS INC.; ADRENAS THERAPEUTICS INC.; PHOENIX TISSUE REPAIR, INC.; NAVIRE PHARMA, INC.; VENTHERA, INC.; MOLECULAR SKIN THERAPEUTICS, INC.; CANTERO THERAPEUTICS, INC.; COA THERAPEUTICS, INC.; PORTAL THERAPEUTICS, INC.; BRIDGEBIO GENE THERAPY RESEARCH, INC.; FERRO THERAPEUTICS, INC.; SUB21, INC.
To: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 066355/0126 →
RELEASE OF SECURITY INTEREST Recorded Jan 18, 2024
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS SUCCESSOR TO U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: BRIDGEBIO PHARMA, INC.; ORIGIN BIOSCIENCES, INC.; EIDOS THERAPEUTICS, INC.; QED THERAPEUTICS, INC.; ADRENAS THERAPEUTICS, INC.; PHOENIX TISSUE REPAIR, INC.
Reel/Frame 066167/0462 →
SECURITY INTEREST Recorded Jan 17, 2024
From: CALCILYTIX THERAPEUTICS INC.; ADRENAS THERAPEUTICS INC.; PHOENIX TISSUE REPAIR, INC.; NAVIRE PHARMA, INC.; VENTHERA, INC.; MOLECULAR SKIN THERAPEUTICS, INC.; CANTERO THERAPEUTICS, INC.; COA THERAPEUTICS, INC.; PORTAL THERAPEUTICS, INC.; BRIDGEBIO GENE THERAPY RESEARCH, INC.; FERRO THERAPEUTICS, INC.; SUB21, INC.
To: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 066342/0154 →
SECURITY INTEREST Recorded Nov 17, 2021
From: BRIDGEBIO PHARMA, INC.; ORIGIN BIOSCIENCES, INC.; EIDOS THERAPEUTICS, INC.; QED THERAPEUTICS, INC.; ADRENAS THERAPEUTICS, INC.; PHOENIX TISSUE REPAIR, INC.
To: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 058144/0302 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2020
From: BOUGNERES, PIERRE; GAO, GUANGPING
To: ADRENAS THERAPEUTICS, INC.
Reel/Frame 053433/0556 →
Continuity (3)
Provisional Application 62640311 · Mar 8, 2018
Provisional Application 62618307 · Jan 17, 2018
Related Publication 20210277365A1 · Sep 9, 2021
References Cited (54)
US 5478745A · Samulski et al. · 1995 [cited by applicant]
US 6136597A · Hope et al. · 2000 [cited by applicant]
US 6287814B1 · Hope et al. · 2001 [cited by applicant]
US 7198951B2 · Gao et al. · 2007 [cited by applicant]
US 7282199B2 · Gao et al. · 2007 [cited by applicant]
US 7906111B2 · Wilson et al. · 2011 [cited by applicant]
US 8865881B2 · Balazs · 2014 [cited by examiner]
US 9587250B2 · Gao et al. · 2017 [cited by applicant]
US 9677089B2 · Gao et al. · 2017 [cited by applicant]
US 9840719B2 · High et al. · 2017 [cited by applicant]
US 10385376B2 · Lattemann et al. · 2019 [cited by applicant]
US 11078247B2 · Fotin-Mleczek · 2021 [cited by examiner]
JP 2002516092A · 2002 [cited by applicant]
WO WO9961601A2 · 1999 [cited by applicant]
WO WO2012115980A1 · 2012 [cited by applicant]
WO WO2015041718A1 · 2015 [cited by applicant]
WO WO2017008154A1 · 2017 [cited by examiner]
WO WO2022198038A1 · 2022 [cited by applicant]
Fischer et al. (Molecular Therapy, 25, 8, 1954-1865, 2017). [cited by examiner]
Zhang et al. (Cancer-Targeted Gene and Cell Therapy, 24, Supp 1, S84-S85, 2016). [cited by examiner]
Perdomini et al. (Gene Therapy, 2017, 24, 275-281). [cited by examiner]
Eclov, et al., Durable CYP21A2 Gene Therapy in Non-Human Primates for Treatment of Congenital Adrenal Hyperplasia, 2019 European Society of Gene & Cell Therapy, Poster, Jan. 1, 2019, 1 page, XP055934324. Retrieved from … [cited by applicant]
Eclov, RJ, et al., Durable CYP21A2 Gene Therapy in Non-Human Primates for Treatment of Congenital Adrenal Hyperplasia, Poster, 1 page. [cited by applicant]
Majowicz et al., Successful Repeated Hepatic Gene Delivery in Mice and Non-human Primates Achieved by Sequential Administration of AAV5 [cited by applicant]
Paneda et al., Safety and Liver Transduction Efficacy of rAAV5-cohPBGD in Nonhuman Primates: A Potential Therapy for Acute Intermittent Porphyria, Human Gene Therapy, Dec. 2013, pp. 1007-1017, vol. 24. [cited by applicant]
International Search Report and Written Opinion issued by the International Searching Authority for Application No. PCT/US2019/013991, dated Mar. 27, 2019, 9 pages. [cited by applicant]
Beltran et al., “rAAV2/5 gene-targeting to rods: dose-dependent efficiency and complications associated with different promoters,” Gene Therapy, 17(9): 1162-1174 (2010). [cited by applicant]
Boshart et al., “A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus,” Cell, 41:521-530 (1985). [cited by applicant]
Bruining et al., “Clinical Case Seminar Fertility and Body Composition after Laparoscopic Bilateral Adrenalectomy in a 30-Year-Old Female with Congenital Adrenal Hyperplasia,” J Clin Endocrinol Metab 86(2):482-484 (2001… [cited by applicant]
El-Maouche et al., “Congenital adrenal hyperplasia”, Lancet 390(10108):2194-2210 (2017). [cited by applicant]
Gastaud et al., “Impaired Sexual and Reproductive Outcomes in Women with Classical Forms of Congenital Adrenal Hyperplasia,” J Clin Endocrinol Metab, 92(4), 1391-1396 (2007). [cited by applicant]
Gmyrek et al., “Bilateral Laparoscopic Adrenalectomy as a Treatment for Classic Congenital Adrenal Hyperplasia Attributable to 21-Hydroxylase Deficiency,” Pediatrics, 109: E28 (2002), 6 pages. [cited by applicant]
Gray et al., “Optimizing Promoters for Recombinant Adeno-Associated Virus-Mediated Gene Expression in the Peripheral and Central Nervous System Using Self-Complementary Vectors,” Hum Gene Ther, 22(9): 1143-1153 (2011). [cited by applicant]
Hahner et al., “High Incidence of Adrenal Crisis in Educated Patients with Chronic Adrenal Insufficiency: A Prospective Study,” J Clin Endocrinol Metab, 100(2): 407-416 (2015). [cited by applicant]
Kurtoglu et al., “Non-Classical Congenital Adrenal Hyperplasia in Childhood,” J Clin Res Pediatr Endocrinol, 9(1): 1-7 (2017). [cited by applicant]
Macapagal et al., “Gene Therapy of 21-Hydroxylase Deficient Mice Utilizing an Adeno-Associated Virus Vector,” The Endocrine Society, Program & Abstracts, 84trh Annual Meeting, Jun. 19-22, 2002, Abstract P1-503, 4 pages. [cited by applicant]
Markmann et al., “Biology of the Adrenal Gland Cortex Obviates Effective Use of Adeno-Associated Virus Vectors to Treat Hereditary Adrenal Disorders,” Human Gene Therapy 29(4):403-412 (2018). [cited by applicant]
Mussolino et al., “AAV-mediated photoreceptor transduction of the pig cone-enriched retina,” Gene Therapy, 18(7): 637-645 (2011). [cited by applicant]
Naiki et al., “Extra-adrenal induction of Cyp21a1 ameliorates systemic steroid metabolism in a mouse model of congenital adrenal hyperplasia,” Endocrine Journal 63(10):897-904 (2016). [cited by applicant]
Perdomini et al., “An AAVrh10-CAG-CYP21-HA vector allows persistent correction of 21-hydroxylase deficiency in a Cyp21-/-mouse model,” Gene Therapy, 24(5):275-281 (2017). [cited by applicant]
Rabinowitz et al., “Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity,” J Viral, 76(2):791-801 (2002). [cited by applicant]
Tajima et al., “Prenatal Dexamethasone Treatment Does Not Prevent Alterations of the Hypothalamic Pituitary Adrenal Axis in Steroid 21-Hydroxylase Deficient Mice,” Endocrinology 140:3354-3362 (1999). [cited by applicant]
Tajima et al., “Restoration of adrenal steroidogenesis by adenovirus-mediated transfer of human cytochrome P450 21-hydroxylase into the adrenal gland of 21-hydroxylase-deficient mice,” Gene Therapy 6:1898-1903 (1999). [cited by applicant]
Thakral and Ghoshal, “miR-122 is a Unique Molecule with Great Potential in Diagnosis, Prognosis of Liver Disease, and Therapy Both as miRNA Mimic and Antimir,” Curr Gene Ther. 15(2): 142-150 (2015). [cited by applicant]
Yanase et al., “Differentiation and regeneration of adrenal tissues: An initial step toward regeneration therapy for steroid insufficiency,” Endocrine Journal, Tokyo, JP 53(4):449-459 (2006). [cited by applicant]
Wang et al., “Sustained correction of bleeding disorder in hemophilia B mice by gene therapy,” Proc. Natl. Acad Sci., USA, 96(7): 3906-3910 (1999). [cited by applicant]
Office Action and Search Report for Chinese Application No. CN20198008414 dated Jan. 18, 2023, 19 pages. [cited by applicant]
Office Action for Japanese Application No. JP20200537156 dated Jan. 6, 2023, 6 pages. [cited by applicant]
Office Action for Japanese Application No. JP20200537156 dated Jun. 21, 2023, 10 pages. [cited by applicant]
Vermeulen, et al., [cited by applicant]
Mattar, et al., Stable human FIX expression after 0.9 G intrauterine gene transfer of self-complementary adeno-associated viral vector 5 and 8 in macaques, Molecular Therapy, Nov. 2011, pp. 1950-1960. [cited by applicant]
McLaughlin, et al., Adeno-associated virus general transduction vectors: analysis of proviral structures, Journal of virology, Jun. 1988, pp. 1963-1973. [cited by applicant]
Office Action for Japanese Application No. JP20200537156 mailed Jan. 19, 2024, 8 pages. [cited by applicant]
Tran, et al., Adrenal gland infection by serotype 5 adenovirus requires coagulation factors, PLoS One, Apr. 2013, 9 pages. [cited by applicant]